Q&A: Page 2

Exclusive interviews with industry leaders


  • Image attribution tooltip
    Stock via Getty Images

    One company's failed drug is this company's 'jewel'

    Dr. Thomas Bock, CEO of Notable, is helping the company develop a ‘new class’ of predictive precision medicines in oncology.

    Meagan Parrish • May 2, 2022
  • Headshot of Alan Millar.
    Image attribution tooltip

    Permission granted by Alan Millar. 

    How an open platform can shake up the drug development process

    TetraScience’s Alan Millar shares why pharma is rethinking data integration in the race to be faster, better and more effective.

    Kim Ribbink • April 28, 2022
  • Vital sign monitor in tablet PC.
    Image attribution tooltip
    iStock via Getty Images

    Real-world data is making drug development more true to life

    How RWD is moving from the background to the spotlight in pharma’s development process.

    Kelly Bilodeau • April 26, 2022
  • Scientists examines DNA models in modern Neurological Research Laboratory.
    Image attribution tooltip
    iStock via Getty Images

    How OliX Pharmaceuticals is riding the RNAi wave

    While the company may look like “the new kid on the block,” CEO Dong-ki Lee says the Korean biotech is ready for the global stage.

    Karissa Waddick and Taren Grom • April 25, 2022
  • Image attribution tooltip
    Stock via Getty Images

    The cannabis vanguard: A rare disease company looks to pioneer in the space

    Zynerba’s CEO shares his views on advances in cannabidiol treatments for neuropsychiatric illnesses and the regulatory environment for CBD-based drugs.

    Jared Whitlock • April 21, 2022
  • Psychedelic drugs
    Image attribution tooltip
    iStock via Getty Images

    A psychedelic pill for alcoholism? The CEO of Clearmind Medicine says 'Yes.'

    Known to provide a “euphoric” experience, MEAI started out as a recreational drug used as an alcohol substitute. Now, Adi Zuloff-Shani says it may even treat alcohol addiction.

    Alexandra Pecci • April 21, 2022
  • In this photo illustration, the Facebook and Instagram apps are seen on the screen of an iPhone on October 04, 2021 in San Anselmo, California.
    Image attribution tooltip
    Justin Sullivan / Staff via Getty Images

    How pharma can up its social media game

    Health Union’s VP of community development, Sara Hayes, discusses how pharma marketers can better reach online patient communities. 

    Karissa Waddick • April 18, 2022
  • Busy traffic in Downtown Los Angeles at dusk.
    Image attribution tooltip
    Yongyuan via Getty Images

    Biotech goes Hollywood

    A few years ago, the biotech venture world in LA was almost ‘nonexistent’ — now Joseph Panetta, CEO of Biocom California, says the region is undergoing a major change.

    Taren Grom • April 13, 2022
  • Image attribution tooltip
    Stock via Getty Images

    Down but not out: How AVEO's CEO steered the company past an FDA rejection

    Michael Bailey explains why focusing on the patient helped AVEO clear regulatory hurdles to bring a new cancer drug across the finish line.

    Kim Ribbink • April 5, 2022
  • Image attribution tooltip
    Real Chemistry/PharmaVoice

    Lessons from improv: Shankar Narayanan's 'yes, and' approach to healthcare leadership

    Real Chemistry's CEO is bringing a unique set of skills to the role as he sets off on a company-wide listening tour.

    Taren Grom • April 4, 2022
  • Image attribution tooltip
    Stock via Getty Images

    Time-saving tech lights Alcon's path into digital innovation

    Kevin Yapp, global head or omni-channel transformation at the Swiss eye health company shares why the customer should be a  North Star when developing digital tools.

    Kim Ribbink • April 4, 2022
  • Image attribution tooltip

    Sangamo Therapeutics

    Sangamo has its finger on the next evolution of gene editing

    Sangamo Therapeutics' CEO Sandy Macrae is bullish on his company’s ability to transform the genomic medicine arena.

    Taren Grom • March 31, 2022
  • Image attribution tooltip
    Stock via Getty Images

    Rare Patient Voice's president is striving to create a five-star experience for patients

    Successful clinical trial recruitment depends on listening to and empowering patients.

    Kim Ribbink • March 23, 2022
  • Image attribution tooltip
    Stock via Getty Images

    Why Astellas is adopting a 'focus area approach' to partnerships

    Chief Strategy Officer, Naoki Okamura, explains why new trends and innovations require a different approach to alliances.

    Kim Ribbink • March 22, 2022
  • Image attribution tooltip
    Retrieved from PharmaVOICE on March 21, 2022

    BioMarin's new global head of advocacy is tackling the holy grail of patient engagement

    In her new role, Dr. Roz is keeping her patient-first approach.

    Taren Grom • March 21, 2022
  • Image attribution tooltip

    Novartis' manufacturing facility for innovative cell and gene therapies in Stein, Switzerland. Permission granted by Novartis.

    How Novartis kept its supply chain intact during COVID-19

    In an agile pivot, Amit Nastik led Novartis’ manufacturing operations through the pandemic without losing supply chain reliability. 

    Taren Grom • March 16, 2022
  • Image attribution tooltip

    Image courtesy of Medigene.

    Medigene's CEO on striking a collaboration deal with BioNTech

    The two companies recently announced a $29 million collaboration. 

    Jared Whitlock • March 15, 2022
  • Image attribution tooltip

    Permission granted by Sanjeev Luther.

    Clearing hurdles in rare cancer drug development

    Rafael’s CEO, Sanjeev Luther, explains why flexibility and agility are keys to success in the rare cancer space.

    Kim Ribbink • March 14, 2022
  • Image attribution tooltip
    Stock via Getty Images

    Liquid biopsy is a multibillion-dollar market, and InterVenn is looking to take advantage

    The company’s CEO explains how its liquid biopsy tests target a unique, untapped layer of biology.

    Taren Grom • March 14, 2022
  • headshot
    Image attribution tooltip
    Permission granted by Terry Weber

    Biote CEO: Employers need to normalize women's health issues in the workforce

    A survey by Biote reveals the impact of menopause on working women.

    Robin Robinson • March 14, 2022
  • Image attribution tooltip

    Image courtesy of Ultragenyx.

    Ultragenyx's CEO on building a 'next-gen' rare disease company

    How Dr. Emil Kakkis is maintaining the soul of a startup while undergoing growth.

    Kim Ribbink • March 9, 2022
  • Image attribution tooltip

    Permission granted by Ramona Sequeira.

    Ramona Sequeira breaks PhRMA's glass ceiling

    A few weeks ago, PhRMA, the industry’s largest trade group, announced that Sequeira has officially become chair of the organization’s board of directors. She is the first woman — and first woman of color — to take on the job.

    Taren Grom • March 7, 2022
  • Image attribution tooltip

    Permission granted by Andrew Hopkins.

    Exscientia scored the largest AI deal with a Big Pharma to date — but it's just getting started

    The company’s CEO on the road ahead for AI capabilities in pharma.

    Meagan Parrish • March 4, 2022
  • Image attribution tooltip
    Stock via Getty Images

    Candel's CEO looks to help ignite a new era of cancer treatments

    Candel Therapeutics is advancing a next-gen approach in oncology: using viruses to kill cancer cells at the site of injection.

    Taren Grom • Feb. 28, 2022
  • Image attribution tooltip
    Stock via Getty Images

    Why plasma derived therapies have a unique edge in rare diseases

    Takeda's head of PDT R&D explains how the Japanese drug giant is advancing these emerging treatments.

    Kim Ribbink • Feb. 25, 2022